Unicycive Therapeutics
UNCY
12 hedge funds and large institutions have $571K invested in Unicycive Therapeutics in 2022 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 3 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
0.15% less ownership
Funds ownership: 0.79% → 0.64% (-0.15%)
20% less funds holding
Funds holding: 15 → 12 (-3)
42% less capital invested
Capital invested by funds: $992K → $571K (-$421K)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAPTRUST Financial Advisors
Raleigh,
North Carolina
|
+$13.8K |
| 2 |
Renaissance Technologies
New York
|
+$1.39K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$7 |
| 4 |
Wells Fargo
San Francisco,
California
|
+$7 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University
Redwood City,
California
|
-$135K |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$14K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$13K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$4K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$2.42K |
UNCY Hedge Fund Activity: Q3 2022 in Review
12 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Unicycive Therapeutics (UNCY) for Q3 2022, worth a combined $571K — down 42% from $992K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of UNCY and 1 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 3 added.
The largest buyer was CAPTRUST Financial Advisors, opening a new position worth an estimated $13.8K. The largest seller was Board of Trustees of The Leland Stanford Junior University, cutting an estimated $135K.
- 12 institutional investors held Unicycive Therapeutics (UNCY) as of Q3 2022, down from 15 in Q2 2022.
- Funds reported $571K of Unicycive Therapeutics stock for Q3 2022, down 42% quarter-over-quarter.
- 1 fund opened new Unicycive Therapeutics positions in Q3 2022 and 3 closed out, a net change of -2 holders.
- The largest Unicycive Therapeutics buyer in Q3 2022 was CAPTRUST Financial Advisors, an estimated $13.8K added.
- The largest Unicycive Therapeutics seller in Q3 2022 was Board of Trustees of The Leland Stanford Junior University, an estimated $135K sold.
Based on aggregated 13F filings for Q3 2022.